drugset / Trial / NCT00669162

Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer

NCT00669162

Phase 1/2 Completed 27 enrolled University of Kansas Medical Center
NaSingle-groupOpen-labelTreatment

Summary

Following a radical prostatectomy and lymph node sampling, eligible patients will undergo post-operative radiation therapy, concurrent weekly docetaxel chemotherapy , and hormonal therapy (Casodex daily and Zoladex every 3 months for 2 times or Lupron 22.5 mg im every 3 months for 2 times).

Timeline

Start
2012-08
Primary completion
2016-08
Completion
2017-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Bicalutamide Other / unclassified 50 mg Oral
Subject Docetaxel Small molecule 20 mg/m2 Intravenous
Subject Goserelin Other / unclassified 10.8 mg Subcutaneous
Subject Leuprolide Other / unclassified 22.5 mg Intramuscular

Indications